Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
...
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
- Conditions
- Interventions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1289
- Registration Number
- NCT01285609
- Locations
- ๐บ๐ธ
Sharp Memorial Hospital, San Diego, California, United States
๐บ๐ธSt. Francis Hospital & Health Centers, Indianapolis, Indiana, United States
๐บ๐ธDurham Va Medical Center (111g), Durham, North Carolina, United States
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1673
- Registration Number
- NCT01274338
- Locations
- ๐บ๐ธ
Maine Center for Cancer Medicine-Scarborough, Scarborough, Maine, United States
๐บ๐ธYork Hospital, York, Maine, United States
๐บ๐ธSpectrum Health Big Rapids Hospital, Big Rapids, Michigan, United States
Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2013-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT01245556
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
๐บ๐ธJedd D. Wolchok, Md,Phd, New York, New York, United States
Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2016-08-12
- Lead Sponsor
- National Center for Tumor Diseases, Heidelberg
- Target Recruit Count
- 25
- Registration Number
- NCT01216696
- Locations
- ๐ฉ๐ช
NCT, Dep. of Medical Oncology, Heidelberg, Germany
Neoadjuvant Ipilimumab in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT01194271
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2023-07-19
- Target Recruit Count
- 73
- Registration Number
- NCT01176474
- Locations
- ๐บ๐ธ
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 245
- Registration Number
- NCT01134614
- Locations
- ๐บ๐ธ
Iowa Methodist Medical Center, Des Moines, Iowa, United States
๐บ๐ธIowa-Wide Oncology Research Coalition NCORP, Des Moines, Iowa, United States
๐บ๐ธMission Cancer and Blood - Des Moines, Des Moines, Iowa, United States
Ipilimumab + Temozolomide in Metastatic Melanoma
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT01119508
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 837
- Registration Number
- NCT01057810
- Locations
- ๐บ๐ธ
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
๐บ๐ธBaptist Cancer Institute, Jacksonville, Florida, United States
๐บ๐ธMd Anderson Cancer Center Orlando, Orlando, Florida, United States
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 127
- Registration Number
- NCT01024231
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Nassau, New York, New York, United States
๐บ๐ธMedstar Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
๐บ๐ธHillman Cancer Research Pavilion, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.